Perspective Therapeutics to present at World Molecular Imaging Congress

Perspective Therapeutics announced that it will have two presentations at the upcoming World Molecular Imaging Congress 2023, hosted by the World Molecular Imaging Society. The conference is being held in Prague, Czech Republic, from September 5-9. Presentation One: Title: Targeted Alpha Therapy for Neuroendocrine Tumors: Therapeutic Efficacy and Dosimetry Analysis of (212Pb)VMT-alpha-NET in Preclinical Models: Summary: This presentation highlights the potential for lead-based targeted alpha particle therapy, using (212Pb)VMT-alpha-NET, in effectively treating neuroendocrine tumors. In a tumor xenograft mouse model, treatment with fractionated dosing of 212Pb-VMT-alpha-NET resulted in 70% complete response and an 80% survival rate at 120 days. Presentation Two: Title: Cucurbit(7)uril-adamantane host:guest pretargeting with 203Pb-labeled radioligands in xenograft models: Summary: In this presentation, favorable radiochemical and in vivo characteristics of novel radioligand (203Pb)PSC-PEG3-Adma is described for image-guided alpha-particle therapy. Synthesized with exceptional yield and purity, the radioligand demonstrated rapid and preferential tumor accumulation and lag time longer than other radioligands in development.